RA Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-4,858,260
Closed -$233M 66
2020
Q1
$233M Hold
4,858,260
7.37% 2
2019
Q4
$228M Hold
4,858,260
6.91% 3
2019
Q3
$115M Hold
4,858,260
6.85% 4
2019
Q2
$137M Hold
4,858,260
7.35% 4
2019
Q1
$109M Hold
4,858,260
4.69% 5
2018
Q4
$34M Buy
4,858,260
+1,006,452
+26% +$15.8M 1.98% 15
2018
Q3
$69.7M Hold
3,851,808
3.73% 8
2018
Q2
$38.3M Hold
3,851,808
2.49% 16
2018
Q1
$20.5M Buy
3,851,808
+2,500,000
+185% +$17.9M 1.57% 14
2017
Q4
$11.5M Hold
1,351,808
0.96% 19
2017
Q3
$19.7M Hold
1,351,808
1.78% 17
2017
Q2
$25.3M Hold
1,351,808
2.91% 11
2017
Q1
$28.8M Hold
1,351,808
3.53% 7
2016
Q4
$20.5M Buy
+1,351,808
New +$18.4M 2.91% 8

Other funds holding RARX

RA Capital Management's RARX Position: Q2 2020 in Review

RA Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 4,858,260 shares — an estimated $233M sold.

RA Capital Management first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $233M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • RA Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • RA Capital Management sold 4,858,260 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $233M.
  • RA Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • RA Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $233M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on RA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.